Xenon Pharma director sells 1,190 shares in 10b5-1 plan

Xenon Pharmaceuticals Inc. director Gillian Cannon reported an open-market sale of common shares.

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. director Gillian Cannon reported an open-market sale of common shares. On June 5, 2026, she sold 1,190 Common Shares at an average price of $53.14 per share and now directly holds 1,455 shares.

According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, and were executed solely to cover income tax obligations arising from the vesting of RSUs granted on June 5, 2025.

Insights

Insider transactions analyst

Director’s sale is pre-planned and tied to RSU tax obligations.

Director Gillian Cannon sold 1,190 Common Shares of Xenon Pharmaceuticals Inc. at $53.14 per share on June 5, 2026, leaving her with 1,455 shares held directly. The transaction is coded as an open-market sale.

A key detail is the footnote stating the sale was executed under a Rule 10b5-1 trading plan adopted on August 15, 2025, solely to satisfy income tax obligations from RSUs that vested on June 5, 2025. Such pre-planned, tax-driven trades generally carry limited informational value about the insider’s view of the company.

Insider Trade Summary 10b5-1

Net Seller: 1,190 shares

Net Sell 1 txn

Insider Cannon Gillian

Role Director

Sold 1,190 shs ($63K)

Type	Security	Shares	Price	Value
Sale	Common Shares	1,190	$53.14	$63K

Holdings After Transaction: Common Shares — 1,455 shares (Direct)

Footnotes (1)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.

Key Figures

Shares sold: 1,190 shares Sale price per share: $53.14 per share Shares owned after sale: 1,455 shares +2 more

5 metrics

Shares sold 1,190 shares Common Shares sold on June 5, 2026

Sale price per share $53.14 per share Open-market sale on June 5, 2026

Shares owned after sale 1,455 shares Direct ownership following June 5, 2026 transaction

RSU grant vesting date June 5, 2025 RSUs whose vesting triggered related tax obligations

10b5-1 plan adoption date August 15, 2025 Rule 10b5-1 trading plan governing the sale

Key Terms

Rule 10b5-1 trading plan, RSUs, Common Shares

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

RSUs financial

"solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Common Shares financial

"security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xenon Pharmaceuticals (XENE) report for Gillian Cannon?

Xenon Pharmaceuticals reported that director Gillian Cannon sold 1,190 Common Shares on June 5, 2026. The shares were sold in an open-market transaction at an average price of $53.14 per share, as disclosed in a Form 4 filing.

At what price did Gillian Cannon sell Xenon Pharmaceuticals (XENE) shares?

Gillian Cannon sold her 1,190 Common Shares of Xenon Pharmaceuticals at an average price of $53.14 per share. This price reflects the sale executed on June 5, 2026, according to the company’s Form 4 insider trading disclosure.

How many Xenon Pharmaceuticals (XENE) shares does Gillian Cannon hold after the sale?

After the reported sale, Gillian Cannon directly holds 1,455 Common Shares of Xenon Pharmaceuticals. This post-transaction ownership figure comes directly from the Form 4 and shows her remaining equity position following the June 5, 2026 sale.

Was Gillian Cannon’s Xenon Pharmaceuticals (XENE) share sale part of a 10b5-1 plan?

Yes. The Form 4 footnote states the sale was effected under a Rule 10b5-1 trading plan. The plan was adopted on August 15, 2025 and governed transactions intended to meet income tax obligations tied to RSU vesting.

Why did Gillian Cannon sell Xenon Pharmaceuticals (XENE) shares according to the filing?

The footnote explains the sale was executed solely to satisfy income tax obligations from RSUs that vested on June 5, 2025. This indicates the transaction was mainly tax-driven rather than a discretionary change in her investment exposure.

What type of security did Gillian Cannon sell in Xenon Pharmaceuticals (XENE)?

She sold Common Shares of Xenon Pharmaceuticals. The Form 4 identifies the security as Common Shares, with 1,190 shares sold in a single open-market transaction on June 5, 2026, under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 09:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cannon Gillian

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY CANADA (FEDERAL LEVEL) V5G 4W8

(City) (State) (Zip)

CANADA (FEDERAL LEVEL)

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/05/2026		S(1)		1,190	D	$53.14	1,455	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.

	/s/ Nathaniel Adams, Attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)